Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	2299-2300
Number of pages	2
Journal	New England Journal of Medicine
Volume	388
Issue number	24
DOIs	https://doi.org/10.1056/NEJMc2304782
State	Published - 15 Jun 2023

Access to Document

@article{3aa7e06ac9874645bdfe088486a97117,

title = "Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply",

author = "Silverberg, \{Jonathan I.\} and Emma Guttman-Yassky and \{Gontijo Lima\}, Renata",

year = "2023",

month = jun,

day = "15",

doi = "10.1056/NEJMc2304782",

language = "English",

volume = "388",

pages = "2299--2300",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply

AU - Silverberg, Jonathan I.

AU - Guttman-Yassky, Emma

AU - Gontijo Lima, Renata

PY - 2023/6/15

Y1 - 2023/6/15

UR - https://www.scopus.com/pages/publications/85163902499

U2 - 10.1056/NEJMc2304782

DO - 10.1056/NEJMc2304782

M3 - Letter

C2 - 37314719

AN - SCOPUS:85163902499

SN - 0028-4793

VL - 388

SP - 2299

EP - 2300

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -